Fwd: Evaluation of the Branched-Chain DNA Assay for Measurement of RNA in Formalin-Fixed Tissues.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 8:08 PM
Subject: Evaluation of the Branched-Chain DNA Assay for Measurement of RNA in Formalin-Fixed Tissues.
To: mesothelioma77@gmail.com


[1]J Mol Diagn. 2008 Feb 14;
Knudsen BS, Allen AN, McLerran DF, Vessella RL, Karademos J, Davies JE, Maqsodi B, McMaster GK, Kristal AR

We evaluated the branched-chain DNA (bDNA) assay QuantiGene Reagent System to measure RNA in formalin-fixed, paraffin-embedded (FFPE) tissues. The QuantiGene Reagent System does not require RNA isolation, avoids enzymatic preamplification, and has a simple workflow. Five selected genes were measured by bDNA assay; quantitative polymerase chain reaction (qPCR) was used as a reference method. Mixed-effect statistical models were used to partition the overall variance into components attributable to xenograft, sample, and assay. For FFPE tissues, the coefficients of reliability were significantly higher for the bDNA assay (93-100%) than for qPCR (82.4-95%). Correlations between qPCRFROZEN, the gold standard, and bDNAFFPE ranged from 0.60 to 0.94, similar to those from qPCRFROZEN and qPCRFFPE. Additionally, the sensitivity of the bDNA assay in tissue homogenates was 10-fold higher than in purified RNA. In 9- to 13-year-old blocks with poor RNA quality, the bDNA assay allowed the correct identification of the overexpression of known cancer genes. In conclusion, the QuantiGene Reagent System is considerably more reliable, reproducible, and sensitive than qPCR, providing an alternative method for the measurement of gene expression in FFPE tissues. It also appears to be well suited for the clinical analysis of FFPE tissues with diagnostic or prognostic gene expression biomarker panels for use in patient treatment and management.



___
Source: http://www.hubmed.org/display.cgi?uids=18276773
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Bayer halts trial of lung cancer treatment (TODAYonline)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Feb 19, 2008 at 8:35 AM
Subject: Bayer halts trial of lung cancer treatment (TODAYonline)
To: mesothelioma77@gmail.com


Bayer logo on a building in Berlin. German drug group Bayer said Monday that it had halted trials of its leading cancer treatment Nexavar for one of the main forms of lung cancer.

Mon, 18 Feb 2008 19:37:12 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11iodpo89/*http%3A//www.todayonline.com/articles/238295.asp
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: LegalView Offers Traumatic Brain Injury Victims Information on New Interview Technique To Restore Long-Term Memory ... (PRWeb)

---------- Forwarded message ----------
From: Yahoo! News Search Results for mesothelioma <rssfwd@rssfwd.com>
Date: Sun, Feb 17, 2008 at 6:00 PM
Subject: LegalView Offers Traumatic Brain Injury Victims Information on New Interview Technique To Restore Long-Term Memory ... (PRWeb)
To: mesothelioma77@gmail.com


LegalView reports a new scientific research on an interviewing technique that will help traumatic brain injury patients retrieve long-term memory. LegalView discovered the recent study on the autobiographic interview technique, which is helping brain injury victims with memory impairment. (PRWeb Feb 17, 2008) Read the full story at http://www.prweb.com/releases/2008/02/prweb703693.htm

Sun, 17 Feb 2008 08:18:14 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/mesothelioma/SIG=11p33u2ns/*http%3A//www.prweb.com/releases/2008/02/prweb703693.htm
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 8:08 PM
Subject: Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination.
To: mesothelioma77@gmail.com


[1]Cell Cycle. 2008 Feb 11; 7(5):
Berglind H, Pawitan Y, Kato S, Ishioka C, Soussi T

Cancer cell lines are essential tools used in many areas of biomedical research. Using the last release of the UMD_p53 database (2007)(1), we analysed the p53 status of 1,211 cell lines published between 1989 and 2007. p53 mutations in cell lines from various types of cancers display a striking similarity in the distribution of mutations and in the pattern of mutational events compared to tumours, indicating that they are representative of the cells from which they were derived. Analysis of the residual transcriptional activity of p53 mutants identified in cell lines that displayed two different p53 mutations show that there is a high frequency of weak mutations that are paired with more potent mutations suggesting a driver / passenger configuration. Strikingly, we found discrepancies in the p53 status for 23% (88/384) of cell lines, for which the p53 status was established.



___
Source: http://www.hubmed.org/display.cgi?uids=18277095
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Unusual Features of Malignant Pleural Mesothelioma Metastatic to the Mediastinal Lymph Nodes.

----- Forwarded Message ----
From: HubMed - mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Thursday, February 28, 2008 2:03:45 PM
Subject: Unusual Features of Malignant Pleural Mesothelioma Metastatic to the Mediastinal Lymph Nodes.

[1]Appl Immunohistochem Mol Morphol. 2008 Feb 8;
Wagner D, Bourne PA, Yang Q, Goldman BI, Lewis JS, Xu H

Malignant pleural mesothelioma (MPM) is a rare cancer that metastasizes to mediastinal lymph nodes (MLNs). The diagnosis of MPM metastatic to MLNs may not be straightforward. We describe 3 cases to highlight unusual entities of MPM metastatic to MLNs as follows. One patient with a history of T3N1M0, poorly differentiated esophageal adenocarcinoma and malignant melanoma presented with shortness of breath, mediastinal lymphadenopathy, and pleural effusion; metastatic disease was clinically suspected. Unexpectedly, immunohistochemical studies supported the diagnosis of MPM metastatic to the MLN on biopsy. In another case, mesothelial cell inclusions were initially diagnosed based on the light microscopy, immunohistochemistry, and lack of pleural thickening on computed tomography studies. Subsequent fine needle aspiration of an enlarged cervical lymph node found an atypical mesothelial proliferation, and metastatic mesothelioma was strongly suspected. Video-assisted thoracoscopic examination showed small visceral nodules, and pleural biopsy was diagnosed as malignant epithelioid mesothelioma. The mediastinal and cervical lymph node biopsies were reinterpreted as positive for MPM. In the last case, MLN biopsy showed a malignant epithelioid cell proliferation. Calretinin, CK5/6, WT-1, D2-40, p63, and CD5 were immunohistochemically detected in the tumor but epithelial markers and TTF-1 were negative. Metastatic mesothelioma was considered based on immunohistochemistry and computerized tomography finding of pleural thickening even though p63 and CD5 positivity were unusual. In summary, MPM may present as mediastinal lymphadenopathy with metastases or it may be a concurrent neoplasm with other malignancies or shows an unusual immunohistochemical staining pattern. Caution should be used when diagnosing mesothelial cell inclusions in MLNs.



___
Source: http://www.hubmed.org/display.cgi?uids=18301236
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

---

Looking for last minute shopping deals? Find them fast with Yahoo! Search.

Fwd: Multiple Primary Tumors in Differentiated Thyroid Carcinoma and Relationship to Thyroid Cancer Outcome.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 8:08 PM
Subject: Multiple Primary Tumors in Differentiated Thyroid Carcinoma and Relationship to Thyroid Cancer Outcome.
To: mesothelioma77@gmail.com


[1]Endocr J. 2008 Feb 15;
Omür O, Ozcan Z, Yazıcı B, Akgün A, Oral A, Ozkılıç H

Patients with differentiated thyroid carcinoma (DTC) have long-life expectancy and are at risk for developing a second primary cancer. Aim of this study was to assess the occurrence of DTC in conjunction with other primary neoplasms. It was also aimed to explore the possibility of synchronous or metachronous other malignancies having an impact on clinical course of thyroid carcinoma. Clinical records of 1680 DTC patients treated and followed in our institution over last twenty years were reviewed. Forty-five second primary tumors were found in 42 patients. These patients were classified into 3 groups as antecedent (group I), synchronous (group II) or subsequent (group III) according to the timing of occurrence of non-thyroidal malignancy. The initial characteristics of thyroid neoplasm were compared between patients with DTC plus another tumor and DTC only. Kaplan-Meier Survival Analysis was used to estimate the survival probability for patients with DTC alone and DTC plus another primary tumor. There were 15 synchronous and 30 metachronous tumors in 42 patients. Three of them had triple tumors. The most common second primary was lympho-haematological and upper aero digestive system tumors in group I and II respectively, whereas a variety of tumors were noted in group III. Despite the more common occurrence of unfavourable prognostic factors in patients with multiple cancers than thyroid cancer alone, complete response to radioiodine therapy and recurrence free survival rate was similar in both groups (p>0,05). The results of the current series imply that the occurrence of multiple primary tumors is not uncommon in patients with DTC. Close medical surveillance and the use of advanced screening modalities might lead to the detection of second primary tumors in DTC. However, the presence of second primary seems not to affect the clinical course of DTC.



___
Source: http://www.hubmed.org/display.cgi?uids=18277003
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Onyx Halts Lung Cancer Study (TheStreet.com)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Feb 19, 2008 at 8:35 AM
Subject: Onyx Halts Lung Cancer Study (TheStreet.com)
To: mesothelioma77@gmail.com


There were hopes for as much as $1 billion in additional revenue from nexavar as lung cancer treatment.

Tue, 19 Feb 2008 12:05:11 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=13avrl3lh/*http%3A//www.thestreet.com/s/onyx-halts-lung-cancer-study/newsanalysis/biotech/10403855.html?puc=_tscrss
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Reuniting?

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Feb 17, 2008 at 6:11 PM
Subject: Reuniting?
To: mesothelioma77@gmail.com

Filed under: Anglophilia > Lily Allen The walk of shame! Lily Allen was seen leaving a fella's house in London on Sunday morning.

Sun, 17 Feb 2008 19:02:48 GMT

---

Source: http://perezhilton.com/2008-02-17-reuniting
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Timeline: Kosovo

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Feb 17, 2008 at 6:11 PM
Subject: Timeline: Kosovo
To: mesothelioma77@gmail.com

A chronology of key events 12th century - Kosovo lies at the heart of the Serbian empire, under the Nemanjic dynasty.

Sun, 17 Feb 2008 19:59:21 GMT

---

Source: http://news.bbc.co.uk/1/hi/world/europe/country_profiles/3550401.stm
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc